Literature DB >> 11326478

Longitudinal study of rheumatoid arthritis patients discloses sustained elevated serum levels of soluble CD106 (V-CAM).

M N Kolopp-Sarda1, F Guillemin, I Chary-Valckenaere, M C Béné, J Pourel, G C Faure.   

Abstract

OBJECTIVE: To appreciate the evolution of serum angiogenic and/or adhesion molecules levels during a long term follow-up of rheumatoid arthritis (RA) patients.
METHODS: Serum levels of 5 soluble adhesion/angiogenesis glycoproteins (VEGF, CD31, CD54, CD62E, CD106) were measured in Elisa in samples collected over 6 years in a cohort of 43 RA patients with monitored clinical parameters of disease activity and severity.
RESULTS: RA patients had significantly higher levels (p < 0.0001) of sCD106 (VCAM-1) than control subjects. Conversely, the levels of soluble VEGF, CD31, CD54 and CD62E were normal or lower than normal. No statistically significant time effect was noted. No effect either was noted as related to the therapeutic agents taken by the patients.
CONCLUSION: The sustained elevated serum levels of sCD106 observed here imply that this molecule might be related to the chronicity and progression of RA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11326478

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  5 in total

1.  Comparison of soluble adhesion molecules in juvenile idiopathic arthritis between the active and remission stages.

Authors:  C-Y Chen; C-H Tsao; L-S Ou; M-H Yang; M-L Kuo; J-L Huang
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

2.  Decrease in circulating endothelial cell adhesion molecule and thrombomodulin levels during oral iloprost treatment in rheumatoid arthritis patients: preliminary results.

Authors:  Michael W J Boehme; Ino K Gao; Cornelia Norden; Ernst-Martin Lemmel
Journal:  Rheumatol Int       Date:  2005-02-08       Impact factor: 2.631

3.  Cell adhesion molecules and plasminogen activator inhibitor type-1 (PAI-1) in patients with rheumatoid arthritis: influence of metabolic syndrome.

Authors:  Marcelo Cândido de Sá; Andréa Name Colado Simão; Fabiano Aparecido de Medeiros; Tatiana Mayumi Veiga Iriyoda; Neide Tomimura Costa; Daniela Frizon Alfieri; Tamires Flauzino; Bruno Alexandre Sekiguchi; Marcell Alysson Batisti Lozovoy; Edna Maria Vissoci Reiche; Michael Maes; Isaias Dichi
Journal:  Clin Exp Med       Date:  2018-07-14       Impact factor: 3.984

4.  PECAM-1 gene polymorphisms and soluble PECAM-1 level in rheumatoid arthritis and systemic lupus erythematosus patients: any link with clinical atherosclerotic events?

Authors:  Omer Nuri Pamuk; Hilmi Tozkir; Mehmet Sevki Uyanik; Hakan Gurkan; Fatih Saritas; Julide Duymaz; Salim Donmez; Metin Yazar; Gulsum Emel Pamuk
Journal:  Clin Rheumatol       Date:  2014-09-10       Impact factor: 2.980

5.  Increased Soluble VCAM-1 and Normal P-Selectin in Cystic Fibrosis: a Cross-Sectional Study.

Authors:  Jan K Nowak; Irena Wojsyk-Banaszak; Edyta Mądry; Andrzej Wykrętowicz; Patrycja Krzyżanowska; Sławomira Drzymała-Czyż; Agata Nowicka; Andrzej Pogorzelski; Ewa Sapiejka; Wojciech Skorupa; Mariusz Szczepanik; Aleksandra Lisowska; Jaroslaw Walkowiak
Journal:  Lung       Date:  2017-06-23       Impact factor: 2.584

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.